Furthermore, the AKT inhibitor MK2206 and activator SC79 respectively counteracted the effects of ZYX overexpression and ZYX knockdown on the proliferation, migration, and invasiveness of HCC cells. This evidence concerns the gene AKT1 and hepatocellular carcinoma.